Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
496
datasets available to search
ShareScore release 0.9.0
Dataset results
496 results for “Randomised controlled trial”
Data from: Ibobbly mobile health intervention for suicide prevention in Australian Indigenous youth: a pilot randomised controlled trial
Open the record for dataset details and reuse information.
Data from: Economic evaluation of a general hospital unit for older people with delirium and dementia (TEAM randomised controlled trial)
Open the record for dataset details and reuse information.
Data from: Umbilical vein oxytocin for the treatment of retained placenta (Release Study): a double-blind, randomised controlled trial.
Open the record for dataset details and reuse information.
Effect of engaging communities in decision-making and action through traditional and religious leaders on vaccination coverage in Cross River State, Nigeria: a cluster randomised-control trial
Open the record for dataset details and reuse information.
Data from: Effect of methylcobalamin on capecitabine-induced hand-foot syndrome in patients with HER2-negative early breast cancer: A multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Open the record for dataset details and reuse information.
Data from: Strategies for understanding and reducing the Plasmodium vivax and Plasmodium ovale hypnozoite reservoir in Papua New Guinean children: a randomised placebo-controlled trial and mathematical model
Open the record for dataset details and reuse information.
Data from: Comparison of self-perceived cardiovascular disease risk among smokers with Framingham and PROCAM scores: a cross-sectional analysis of baseline data from a randomised controlled trial
Open the record for dataset details and reuse information.
MiRoR14 - P3 - Effect of an editorial intervention to improve the completeness of reporting of randomised trials: a randomised controlled trial
<p>Protocol:</p> <ul> <li><strong><em>RCT Protocol Ammendment 2.pdf</em></strong> is the final version of the RCT protocol. </li> </ul> <p>R scripts used:</p> <ul> <li><strong><em>Power RCT_bootstrap_paper.R</em></strong> was the code used for the power analysis. </li> <li><strong><em>server.R</em></strong> and <strong><em>ui.R</em></strong> were part of the Shiny application used for the randomisation process.</li> <li><strong><em>Primary Outcome analysis.R</em></strong> was the code used for the primary outcome analysis. </li> </ul> <p>These files can be found below.</p>
DATASET OF "Intrathecal morphine and sleep apnoea severity in patients undergoing hip arthroplasty: a randomised, controlled, triple- blinded trial"
<p><strong>Background: </strong>Intrathecal morphine prolongs analgesia after surgery, but has been implicated in postoperative respiratory depression or apnoeic episodes. However, this has not been investigated in a prospective trial using respiratory polygraphy. This randomized controlled triple-blinded trial tested the hypothesis that intrathecal morphine increases sleep apnoea severity, measured using respiratory polygraphy.</p> <p><strong>Methods: </strong>Sixty patients undergoing hip arthroplasty under spinal anaesthesia received either 15 mg isobaric bupivacaine 0.5% with 0.5 mL normal saline 0.9% (control group) or 15 mg isobaric bupivacaine 0.5% with 0.5 mL intrathecal morphine 100 µg (intrathecal morphine group). Respiratory polygraphy was performed before surgery and on the first and third postoperative nights. The primary outcome was the apnoea-hypopnoea index in the supine position (supine AHI) on the first postoperative night. Secondary outcomes included supine AHI on the third postoperative night, oxygen desaturation index (ODI) and respiratory rate in the first and third postoperative nights.</p> <p><strong>Results: </strong>On the first postoperative night, mean (95% confidence interval) values for supine AHI were 20.6 (13.9–27.3) and 21.2 (12.4–30.0) events/h in the control and intrathecal morphine groups, respectively (p=0.90). There were no significant between-group differences for any of the secondary outcomes, except for a significantly higher central and mixed apnoea index preoperatively and significantly lower mean SpO<sub>2</sub> on the third postoperative night in the control group.</p> <p><strong>Conclusions: </strong>Intrathecal morphine did not increase sleep apnoea severity, when measured using respiratory polygraphy. Of note, all patients had an increased number of apnoeic episodes on the third postoperative night.</p>
Probiotic-prebiotic therapy improved constipation and gut motility in Parkinson's disease: Randomised controlled trial
<p><b>Objective</b>: We determined the effectiveness of a multi-strain probiotic-prebiotic combination on constipation symptoms and gut motility in PD patients with constipation.</p> <p><b>Methods: </b>PD<b> </b>patients with constipation (ROME III criteria) were randomized to receive a multi-strain probiotic (<i>Lactobacillus sp</i> and <i>Bifidobacterium sp at </i>30 X 10<sup>9</sup> CFU) with fructo-oligosaccaride (prebiotic) or placebo (fermented milk) twice daily for 8 weeks. Primary outcomes were changes in the presence of constipation symptoms using 9 items of Garrigues Questionnaire (GQ), which included an item on bowel opening frequency. Secondary outcomes were whole gut transit time (WGTT), quality of life (PDQ39-SI), motor (MDS-UPDRS) and non-motor symptoms (NMSS).</p> <p><strong>Results:</strong> Of 55 recruited<b>, </b>48 patients completed the study: 22 received probiotic and 26 received placebo. At 8 weeks, the item on bowel opening frequency (BOF) of GQ showed a higher mean weekly BOF in the probiotic group compared to placebo [4.18 (SD 1.44) vs 2.81(SD 1.06), (mean difference 1.37, 95% CI 0.68, 2.07, uncorrected <i>p</i><0.001). Patients in the probiotic group reported five times higher odds (odds ratio=5.48, 95% CI 1.57, 19.12, uncorrected <i>p</i>=0.008) for increasing BOF (< 3 to 3-5 to >5 times/week) compared to the placebo group. Between-group differences were observed in the WGTT [77.32 (SD 55.35) hours vs 113.54 (SD 61.54) hours], (mean difference -36.22, 95% CI -68.90, -3.54, uncorrected <i>p</i>=0.030) and the mean change in WGTT [58.05 (SD 59.30) vs 20.73 (60.48) hours], (mean difference 37.32, 95% CI 4.00, 70.63, uncorrected <i>p</i>=0.028). No between-groups differences were observed in the NMSS, PDQ39-SI, MDS-UPDRS II, III, scores. Four patients in the probiotics group experienced mild reversible side effects.</p> <p><b>Conclusion:</b> This study provides Class I evidence that consumption of multi-strain probiotics with prebiotic over 8 weeks improved bowel opening frequency and whole gut transit time.</p>
Data from: Impact of numerical information on 'risk knowledge' regarding human papillomavirus (HPV) vaccination among schoolgirls: a randomised controlled trial
Introduction: In Germany the implementation of HPV vaccination for women 12-17 years of age was accompanied by various campaigns. Evidence based information including numerical data was not provided. However, standard information leads to overestimation of cancer risk and effects of HPV vaccination. Confidence in children's ability to deal with numerical data is low, especially in disadvantaged pupils. The aim of the present study was to compare the effects of a standard leaflet with an information leaflet supplemented with numerical data on 'risk knowledge' regarding HPV vaccination among schoolgirls. Methods: Randomised-controlled short-term trial. All 108 schoolgirls of seven school classes were asked to participate and 105 agreed. Participants were vocational schoolgirls who were preparing for grade 10 graduation and who were members of the target group for HPV vaccination. The control group was asked to read a standard leaflet on HPV vaccination of the German Women's Health Network. The intervention group received the same leaflet, but it was supplemented with numerical information on cancer risk and assumed effects of the HPV vaccination on cancer prevention. As baseline characteristics we surveyed: age, vaccination status, attitude towards HPV vaccination and aspects regarding migration background. The primary end point was 'risk knowledge'. Questionnaire surveys were performed under experimental conditions. Individual randomisation, participants, and intention-to-treat data analyses were blinded. The study was approved by the Ministry of Education and Culture of Schleswig-Holstein and the ethics committee of the Hamburg Chamber of Physicians. Results: We analysed 'risk knowledge' for all 105 randomised participants. Baseline characteristics of the two groups were comparable. Numerical risk information recipients were more likely to give correct answers compared to standard information recipients: Mean value of risk knowledge score (0-5 points): 4.6 ± 1.0 vs. 2.6 ± 1.2 (mean difference 2.0 (95% CI 1.6-2.4)); (P<0.001). Post hoc distractor analysis of single items was performed. Incorrect answers of control participants indicated that cervical cancer risk was highly overestimated whereas total cancer risk was mostly underestimated, and possible impact of HPV vaccination on cancer prevention was overestimated. Conclusion: Supplementing health information on HPV vaccination with numerical data improves 'risk knowledge' among schoolgirls.
Data from: Long-term use benefits of personal frequency-modulated systems for speech in noise perception in patients with stroke with auditory processing deficits: a non-randomised controlled trial study
Objectives: Approximately one in five stroke survivors suffer from difficulties with speech reception in noise, despite normal audiometry. These deficits are treatable with personal Frequency Modulated systems (FMs). This study aimed to evaluate long term benefits in speech reception in noise, after daily 10 week use of personal FMs, in non-aphasic stroke patients with auditory processing deficits. Design: This was a prospective non randomised controlled trial study. Patients were allocated to an intervention care group or standard care subjects group according to their willingness to use the intervention or not. Setting: Tertiary care setting. Participants: Nine non-aphasic subjects with ischemic stroke, normal/near normal audiometry, and auditory processing deficits and with reported difficulties understanding speech in background noise were recruited in the subacute stroke stage (3-12 months after stroke). Interventions: Four patients (intervention care subjects) used the FMs in their daily life over 10 weeks. Five patients (standard care subjects) received standard care. Primary outcome measures: All subjects were tested at baseline (visit 1) and 10 weeks later (visit 2) on a sentences in noise test with the FMs (aided) and without the FMs (unaided). Results: Speech reception thresholds showed clinically and statistically significant improvements in intervention but not in standard care subjects at 10 weeks in both aided and unaided conditions. Conclusions: 10 week use of FM systems by adult stroke patients may lead to benefits in unaided speech in noise perception. Our findings may indicate auditory plasticity type changes and require further investigation.
Data from: Quality of descriptions of treatments: a review of published randomised controlled trials
OBJECTIVES: To be useable in clinical practice, treatments studied in trials must provide sufficient information to enable clinicians and researchers to replicate. We sought to assess the completeness of treatment descriptions in published randomised controlled trials using a checklist and to determine the extent to which peer reviewers and editors comment on the quality of reporting of treatments. DESIGN: Cross-sectional study. SETTING: Trials published in the BMJ, a general medical journal. PARTICIPANTS: 51 trials published in the BMJ were independently evaluated by two raters using the checklist. Reviewers' and editors' comments were also assessed for statements on treatment descriptions. PRIMARY AND SECONDARY OUTCOME MEASURES: Proportion of trials rated as replicable (primary outcome). RESULTS: For 57% (29/51) of the papers, published treatment descriptions were not considered sufficient to allow replication. Most poorly described aspects were the actual procedures involved including the sequencing of the technique (what happened and when) and the physical or informational materials used (e.g. training materials): 53% and 43% not clear, respectively. For a third of treatments, the dose/duration of individual sessions was not clear and for a quarter the schedule (interval, frequency, duration, or timing) was not clear. Although the majority of problems were not picked up by reviewers and editors, when they were detected only about two-thirds were fixed before publication. CONCLUSIONS: Journals wanting to publish research of use to practicing health care professionals need to pay more attention to descriptions of treatments. Our checklist, may be useful for reviewers, and editors and could help ensure important details of treatments are provided before papers are in the public domain.
Data from: Randomised controlled trial of an education and support package for stroke patients and their carers
Objective: Tailoring stroke information and providing reinforcement opportunities are two strategies proposed to enhance the effectiveness of education. This study aimed to evaluate the effects of an education package which utilised both strategies on the knowledge, health and psychosocial outcomes of stroke patients and carers. Design: Multisite, randomised trial comparing usual care with an education and support package. Setting: Two acute stroke units. Participants: Patients and their carers (N=138) were randomised (control n=67, intervention n=71) of which data for 119 participants (control n=59, intervention n=60) were analysed. Intervention: The package consisted of a computer-generated, tailored written information booklet and verbal reinforcement provided prior to, and for 3 months following, discharge. Outcome measures: Outcome measures were administered prior to hospital discharge and at 3-month follow-up by blinded assessors. The primary outcome was stroke knowledge (score range: 0–25). Secondary outcomes were: self-efficacy (1–10), anxiety and depression (0–21), ratings of importance of information (1–10), feelings of being informed (1–10), satisfaction with information (1–10), caregiver burden (carers) (0–13) and quality of life (patients) (1–5). Results: Intervention group participants reported better: self-efficacy for accessing stroke information (adjusted mean difference (MD) of 1.0, 95% CI 0.3 to 1.7, p=0.004); feeling informed (MD 0.9, 95% CI 0.2 to 1.6, p=0.008); and satisfaction with medical (MD 2.0, 95% CI 1.1 to 2.8, p<0.001); practical (MD 1.1, 95% CI 0.3 to 1.9, p=0.008), services and benefits (MD 0.9, 95% CI 0.1 to 1.8, p=0.036) and secondary prevention information (MD 1.7, 95% CI 0.9 to 2.5, p<0.001). There was no significant effect on other outcomes. Conclusions: Intervention group participants had improved self-efficacy for accessing stroke information and satisfaction with information, but other outcomes were not significantly affected. Evaluation of a more intensive intervention in a trial with a larger sample size is required to establish the value of an educational intervention that uses tailoring and reinforcement strategies.
Data from: Efficacy and safety of four weeks' treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomised trial
BACKGROUND: Fluticasone furoate/vilanterol (FF/VI) is a novel once-daily (OD) inhaled corticosteroid/long-acting β2 agonist combination in development for chronic obstructive pulmonary disease (COPD) and asthma. TRIAL DESIGN: A multicentre, randomised, double-blind, parallel-group, placebo-controlled study. METHODS: Participants were patients with moderate-to-severe COPD treated with placebo or FF/VI 400/25 μg OD for 4 weeks. Study objectives were to assess the safety and efficacy of FF/VI 400/25 μg OD administered for 4 weeks via a novel dry powder inhaler. Co-primary end points were change from baseline in weighted mean (wm) heart rate 0–4 h postdose at day 28 and the incidence of adverse events (AEs). Secondary end points included change from baseline in trough forced expiratory volume in one second (FEV1) (23–24 h postdose; day 29) and wm FEV1 (0–4 h postdose; day 28). Patients were randomised to receive FF/VI 400/25 μg or placebo in a 2:1 ratio; all patients and investigators were blinded to active or placebo treatment. RESULTS: 60 patients (mean age 64 years) were randomised (FF/VI: n=40; placebo: n=20), and all contributed data to the analysis. Mean screening post-bronchodilator FEV1 per cent predicted was comparable between groups (FF/VI: 58.5%; placebo: 60.1%). The wm heart rate 0–4 h postdose was similar between groups (difference: 0.6 beats per minute; 95% CI −3.9 to 5.1). More on-treatment AEs were reported in the FF/VI group (68%) compared with the placebo group (50%). The most common drug-related AEs in the FF/VI group were oral candidiasis (8%) and dysphonia (5%). There were no clinically relevant effects on laboratory values, including glucose and potassium, or on vital signs or ECGs/Holters. The FF/VI group had statistically greater improvements compared with placebo in trough FEV1 (mean difference 183 ml) and 0–4 h postdose wm FEV1 (mean difference 236 ml). CONCLUSION: FF/VI has a good safety and tolerability profile and improves lung function compared with placebo in patients with COPD.
Effect of a tailored multidimensional intervention on the care burden among family caregivers of stroke survivors: A randomised controlled trial
<p><span><span><span><b>Introduction:</b> </span></span></span></p> <p><span><span><span>Caring for stroke survivors at home creates high levels of care burden among family caregivers. As the nature of caregiving is multidimensional, previous initiatives at alleviating the care burden using a single approach have not been adequate. It was recommended that future studies focus on tailored interventions that address the needs of family caregivers and combine different approaches to relieve caregivers' burden. However, there is a lack of literature regarding interventions that incorporate these recommendations. The proposed study aims to evaluate the effect of a tailored multidimensional intervention developed by researchers to reduce the care burden among family caregivers of stroke survivors. Based on the perceived needs of family caregivers of stroke survivors, this intervention takes into account scientific recommendations to combine three different approaches: skill-building, psycho-education, and peer support. </span></span></span></p> <p><span><span><span><b>Methods and analysis</b>: Using a prospective, randomized, open-label, parallel-group design, 110 family caregivers were enrolled and randomly assigned to either the intervention group or the control group. The intervention was administered for 6 months and included three home visits and six home-based telephone calls, as well as one peer support session. Family caregivers of the control group received a simple educational booklet during only one home visit. The primary outcome is the care burden as measured <span>using </span>the Zarit Burden Interview. The secondary outcome is the quality of life. Outcomes evaluation was conducted at baseline (T0), Month 3 (T1), and Month 6 (T2). An Independent <i>t</i>-test will be performed to compare the mean values of study variables between the two groups at both T1 and T2. In addition, repeated-measures analysis of variance was conducted to assess changes in effects over time.</span></span></span></p>
Dataset from a randomised cross-over trial of QT response to hyperventilation-induced anxiety and diaphragmatic breathing in patients with stress cardiomyopathy and in control patients
<p>Dataset from a randomised cross-over trial that compared the QT response to hyperventilation-induced anxiety and diaphragmatic breathing in patients with stress cardiomyopathy and age- and sex-matched controls. Pre-registered in the Australia and New Zealand Clinical Trials Registry (ACTRN12618001812280).</p>
Data from: Perioperative medication management: expanding the role of the preadmission clinic pharmacist in a single centre, randomised controlled trial of collaborative prescribing
Objectives: Current evidence to support non-medical prescribing is predominantly qualitative, with little evaluation of accuracy, safety and appropriateness. Our aim was to evaluate a new model of service for the Australia healthcare system, of inpatient medication prescribing by a pharmacist in an elective surgery pre admission clinic (PAC) against usual care, using an endorsed performance framework. Design: Single centre, randomised controlled, two arm trial Setting: Elective surgery pre admission clinic in Brisbane based tertiary hospital Participants: Four hundred adults scheduled for elective surgery were randomised to intervention or control. Intervention: A pharmacist generated the inpatient medication chart to reflect the patient's regular medication, made a plan for medication perioperatively and prescribed VTE prophylaxis. In the control arm, the medication chart was generated by the Resident Medical Officers (RMO). Outcome Measures: Primary outcome was frequency of omissions and prescribing errors when compared against the medication history. The clinical significance of omissions was also analysed. Secondary outcome was appropriateness of VTE prophylaxis prescribing. Results: There were significantly less unintended omissions of medications: 11 of 887 (1.2%) intervention orders compared with 383 of 1217 (31.5%) control (p<0.001). There were significantly less prescribing errors involving selection of drug, dose or frequency: 2 in 857 (0.2%) intervention orders compared with 51 in 807 (6.3%) control (p<0.001). Orders with at least one component of the prescription missing, incorrect or unclear occurred in 20826 of 904 (235%) intervention orders and 445667 of 1034 (4364.5%) control (p<0.001). VTE prophylaxis on admission to the ward was appropriate in 93% of intervention patients and 90% control (p=0.29). Conclusion: Medication charts in the intervention arm contained fewer clinically significant omissions, and prescribing errors, when compared to control. There was no difference in appropriateness of VTE prophylaxis on admission between the two groups. Trial Registration: Registered with ANZCTR – ACTR Number ACTRN12609000426280
Data from: Can recombinant human thrombomodulin increase survival among patients with severe septic-induced disseminated intravascular coagulation: a single-centre, open-label, randomised controlled trial
Objective: To determine whether treatment with recombinant human thrombomodulin (rhTM) increases survival among severe septic patients with sepsis-induced disseminated intravascular coagulation (DIC) Design: Single-center, open-label, randomized controlled trial Setting: Single tertiary hospital Participant: 92 severe septic patients with sepsis-induced DIC Interventions: Patients with DIC scores ≥4, as defined by the Japanese Association of Acute Medicine, were diagnosed with DIC. Randomization was performed by the envelope method. The treatment group (rhTM group, n = 47) was intravenously treated with rhTM within 24 h of admission (day 0), and the control group (n = 45) did not receive any anti-coagulants, except in cases of deep venous thrombosis and pulmonary embolism. Primary and secondary measurements: Data were collected on days 0 (admission), 1, 2, 3, 5, 7, and 10. The primary outcome was survival at 28 and 90 days. The secondary endpoints comprised changes in DIC scores, platelet counts, D-dimer, antithrombin III (ATIII), and C-reactive protein (CRP) levels, and Sequential Organ Failure Assessment (SOFA) scores. All analyses were conducted on an intent-to-treat basis. Main Results: The 28-day survival rates were 84 and 83% in the control and rhTM groups, respectively (p = 0.745, log rank test). The 90-day survival rates were 73% and 72% in the control and rhTM groups, respectively (p = 0.94, log rank test). Meanwhile, the rates of recovery from DIC (<4) were significantly higher in the rhTM group than in the control group (p = 0.001, log rank test). Relative change from baseline of D-dimer levels were significantly lower in the rhTM group than in the control group, on day 3 and 5. Conclusion: rhTM treatment decreased D-dimer levels and facilitated DIC recovery in severe septic patients with sepsis-induced DIC. However, the treatment did not improve survival in this cohort.
A Randomised Controlled Trial to Evaluate the Impact of Complement Theory's Live CoActive Exercise Coaching and Personalized Digital Application on Cancer Survivors' Quality of Life
ClinicalTrials.gov study NCT06397651. IPD Sharing: YES. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.